Flutan

Quick links to important sections

Flutan

Treatment option: Carcinoma

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flutan

Quick Facts

Property Description
Active ingredient Flutamide (INN)
Form Capsule or Tablet
Pharmacological class Nonsteroidal Antiandrogen (NSAA)
General purpose Countering effects of male hormones
Origin Synthetic Compound

What Type of Medicine is Flutan? (Classification and Identity)

Flutan is a synthetic, prescription-only medication that utilizes Flutamide as its active ingredient. It is recognized as a Nonsteroidal Antiandrogen (NSAA), which places it within the larger group of hormonal agents and is classified as an Antineoplastic Agent. This classification is based on its role as a targeted inhibitor.

The medication is chemically defined by the formula C11H11F3N2O3, confirming its identity as a unique, non-steroidal chemical entity. Flutan is administered via the oral route, typically supplied in a capsule or tablet dosage form for systemic effect. Its active compound, Flutamide, is also manufactured under various other trade names, and is often compared to other antiandrogens in the clinical context.

Flutan’s Active Ingredient and Mechanism Principle

The activity of Flutan is centered on Flutamide, which primarily functions as a prodrug and is swiftly converted in vivo into the more potent active metabolite, Hydroxyflutamide. This structural characteristic distinguishes it from direct-acting agents.

Hydroxyflutamide acts as an Androgen Receptor Inhibitor. The core mechanism involves competitively blocking the binding of male hormones, chiefly Testosterone and Dihydrotestosterone (DHT), to the cellular Androgen Receptors (AR). Flutamide competitively blocks androgen binding at these receptors, forming inactive complexes. This action interrupts the hormonal signal promoting cell growth.

What is the General Purpose of Flutan?

The general purpose of Flutan is to serve as a selective antagonist that counters the stimulating effect of male hormones on specific tissues. This systemic approach is clinically recognized to mitigate unwanted cellular activity that is dependent on androgens.

By inhibiting the hormonal signal at the receptor level, the medication helps to reduce the biological impact of androgens. This foundational principle dictates its use in therapeutic strategies aimed at controlling hormone-driven processes.

Regulatory References

  1. Flutamide - StatPearls - NCBI Bookshelf - NIH
  2. Flutamide: MedlinePlus Drug Information
  3. Definition of flutamide - NCI Drug Dictionary - National Cancer Institute

What side effects are possible with Flutan?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety characteristics of Flutan (Flutamide), based strictly on government regulatory documents.


Adverse Reactions by Frequency and Organ System

Adverse effects are categorized in regulatory documents by how often they occur. Examples of events listed as Very Common include hot flushes, diarrhea, nausea, vomiting, decreased libido, and impotence. Effects are grouped by the affected biological system (System-Organ Class or SOC), which includes Gastrointestinal Disorders, Reproductive System and Breast Disorders, Vascular Disorders, and Hepatobiliary Disorders.

Frequency Category Representative Adverse Reactions
Very Common Hot flushes, diarrhea, nausea, vomiting, gynecomastia, impotence
Common Hepatitis, transient abnormal liver function, somnolence, tiredness
Rare Severe skin reactions, blood disorders, neurological effects, and anxiety

Documented Serious Adverse Reactions

Regulatory labeling highlights the potential for severe, clinically significant adverse reactions. The most critical risk documented is Severe Hepatic Injury and Fatal Hepatic Failure, which has led to required safety warnings and monitoring procedures. Other serious reactions documented include Thromboembolic Events (e.g., pulmonary embolism) and the rare development of Malignant Male Breast Neoplasm.

Safety Restrictions and Monitoring Notes

Flutan is contraindicated in women who are or may become pregnant due to the risk of fetal harm, and in patients with pre-existing severe hepatic impairment. Official prescribing information mandates stringent safety monitoring, requiring liver function tests prior to and periodically during treatment, particularly monthly for the first 4 months of therapy. This monitoring addresses the noted time-related pattern where hepatic injury risk is highest during initial exposure.

Overdose and Emergency Response

Flutan Overdose and when to seek help

Property Official Regulatory Statement
Documented Overdose Presentations Signs observed in toxicity studies included hypoactivity (decreased activity), piloerection (goosebumps), slow respiration, ataxia (unsteady movement), lacrimation (tearing of the eyes), anorexia, and emesis (vomiting). In human reports, breast enlargement and tenderness have also been documented. Severe exposure is noted to carry a potential complication of methemoglobinemia.
Emergency Actions Required The regulatory standard requires you to seek immediate medical attention for any suspected overdose. Call emergency services immediately if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.
Overdose Management Constraints Official guidance requires general supportive care, including frequent monitoring of vital signs and close observation of the patient. No specific antidote is known for this medication. Pharmacokinetic constraints specify that Flutan is highly protein bound and is not cleared by hemodialysis.

The regulatory profile establishes that while the specific life-threatening single dose is unknown, the presentation of severe acute symptoms like collapse or trouble breathing mandates immediate medical attention. Supportive care is the required management approach, as procedural constraints officially note the ineffectiveness of hemodialysis and the lack of a specific pharmacological reversal agent.

Therapeutic Uses of Flutan

What Flutan Treats: Main Uses and Benefits

Flutan is commonly used in the management of advanced prostatic carcinoma, a condition where the cancer cells are generally stimulated by male hormones. It provides a key therapeutic benefit by generally helping to address symptoms related to the progression of hormone-driven malignancy. The medication is also applied to moderate the acute symptoms of tumor flare, which may occur during the initiation of other primary hormonal treatments, thereby offering symptomatic support and contributing to easing the overall symptom load during this phase.

In other contexts, Flutan is also considered relevant for treating clinical conditions in women associated with hyperandrogenism. This application is used to address clusters of disruptive symptoms, including symptoms related to androgen-driven hair growth (hirsutism) and stubborn, hormonal acne. This application may assist with addressing these noticeable manifestations, helps improve day-to-day comfort and supports general well-being during symptomatic phases. Flutan is considered relevant for use in conditions such as advanced prostate cancer and specific symptoms of hyperandrogenism in women.

“Flutan is used across domains where additional symptomatic support is needed, aligning with contexts marked by increased discomfort or functional strain.”


Quick Fact: Use in Androgen-Driven Conditions

Flutan may be relevant when supportive symptom management is appropriate for conditions presenting with systemic or localized discomfort driven by male hormones.


Regulatory References

  1. NIH StatPearls review

Eligibility and Restrictions for Use

Who can and cannot use Flutan

The eligibility for Flutamide (Flutan) is strictly defined by regulatory documents, centering on the intended patient population and specific health contraindications. Use is primarily restricted to adult men for the management of the labeled indication.

Eligibility Scope

Classification Eligible Population Restriction/Exclusion Criteria
Allowed Use Adult Males (for indicated use) Not recommended for use in children and adolescents (le 18 years); safety and efficacy are not established in this age group.
Contraindicated None Females who are pregnant or breastfeeding; patients with a known hypersensitivity to flutamide; patients with severe hepatic impairment or significantly elevated baseline serum transaminases (e.g., above two to three times the upper limit of normal).

Condition-Specific Limitations

Flutan is for use only in men and is contraindicated in women, particularly for non-life-threatening conditions. Use requires caution in patients with impaired renal function and those with certain underlying conditions, such as specific cardiac diseases or rare hereditary metabolic disorders related to excipients (e.g., galactose intolerance). These eligibility constraints are based on official government regulatory guidelines.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products

Interaction scope

Category Documented Entities/Restrictions
Medicinal product categories with documented interactions Oral Anticoagulants, CYP1A2/CYP3A4 Enzyme Modulators, QT-prolonging medicinal products, Potentially Hepatotoxic Drugs, LHRH Agonists.
Specific interacting medicines (if explicitly listed) Theophylline, Warfarin.
Mechanistic basis of interactions (only if stated in label) Pharmacokinetic interaction involving CYP1A2 enzyme competition (with Theophylline); Pharmacodynamic interaction resulting in increased prothrombin time (with Warfarin); Flutamide is a substrate for CYP1A2 and CYP3A4.
Timing-based interaction rules (if applicable) Flutan administration must commence simultaneously or at least 24 or more hours before LHRH agonist administration to manage the flare reaction.
Population-specific interaction notes (if applicable) Treatment is contraindicated in severe hepatic impairment (transaminase levels ge 2-3 imes ULN); caution is noted for patients with G6PD deficiency, Hemoglobin M disease, or smokers due to metabolite-related risks.
Interaction-related restrictions Avoid excessive consumption of alcohol; Avoid concomitant use of other potentially hepatotoxic drugs.

Official interaction statements

  • Co-administration with Theophylline is documented to increase Theophylline plasma concentrations due to CYP1A2 enzyme competition.
  • Concurrent use with oral anticoagulants, such as Warfarin, has been reported to cause increases in prothrombin time, requiring close regulatory monitoring.
  • The official label includes a strict contraindication for initiating Flutan in patients with severe hepatic impairment.
  • The administration sequence must be timed such that Flutan begins simultaneously or at least 24 or more hours prior to the LHRH agonist.
  • Food is documented to not affect the bioavailability of Flutamide.

Connection to the overall interaction profile: Regulatory documents establish the interaction structure by documenting specific pharmacokinetic patterns involving CYP enzymes and critical pharmacodynamic effects on coagulation. The profile includes strict regulatory constraints, such as the mandated co-administration timing with LHRH agonists and the classification of severe hepatic impairment as a formal contraindication. Official labeling also explicitly restricts the co-use of substances that carry a risk of additive toxicity, including alcohol and other potentially hepatotoxic medicines.

Mechanism of Action

How Flutan Works

Flutan's mechanism operates via a dual system: a peripheral cellular blockade and a central disruption of hormonal feedback. The active species, Hydroxyflutamide, engages molecular mechanisms that inhibit signaling mediated by androgens.


Blocking the Androgen Receptor (AR)

The drug's primary action involves competitive antagonism of the Androgen Receptor (AR), the key intracellular binding site for Testosterone and DHT. Hydroxyflutamide binds specifically to this receptor, forming a biologically inactive complex that fails to translocate to the cell nucleus . This action suppresses the Androgen-Dependent Gene Expression Pathway, which results in reduced androgen-driven cellular stimulation in sensitive tissues.


Modulating the HPG Axis Feedback

Flutan also affects the body's overall hormonal system by disrupting the negative feedback loop of the Hypothalamic-Pituitary-Gonadal (HPG) Axis. Blockade of ARs in the central nervous system causes a subsequent rise in the pituitary's release of Luteinizing Hormone (LH), which triggers a compensatory surge in circulating testosterone. This compensatory effect represents a key mechanistic limitation of the monotherapy.

Dosage and Administration Information

How to Use Flutan (Fluconazole) — Official Administration Guidelines

This section describes the instructions for the use of fluconazole (Flutan).

Administration Scope

  • Route of Administration: Oral (tablets, powder for oral suspension) or Intravenous (IV) injection.
  • Timing in Relation to Meals: Oral fluconazole may be taken without regard to meals.
  • Frequency and Dosing: The maintenance dose is typically administered once daily. In certain cases, a loading dose equal to twice the usual daily dose may be given on Day 1 to achieve steady-state plasma concentrations more rapidly.

Preparation and Procedural Requirements

  • Oral Suspension Preparation: The powder for oral suspension must be reconstituted by the addition of a specific volume of distilled or purified water, yielding a suspension concentration of either 10 mg/mL or 40 mg/mL. Follow exact volumes specified in the drug labeling.
  • Renal Impairment: Dosage must be reduced in patients with impaired renal function (creatinine clearance less than or equal to 50 mL/min), and the initial loading dose should remain unchanged.
  • Pediatric and Neonatal Use: Dosing for pediatric patients, including term and preterm infants, is calculated on a weight-based (mg/kg) schedule, and specific instructions for dosage and interval (e.g., 9 mg/kg daily or 12 mg/kg daily) must be strictly followed based on the patient's age and gestational status.

Conclusion

These instructions outline the steps for drug delivery via oral or IV routes, emphasizing the need for renal dose adjustment and precise weight-based dosing for younger patient populations. The administration schedule is fundamentally based on a once-daily dosing pattern.

Recent Clinical Evidence

Research evidence / Overview of Studies for Flutan

Evidence for Use in Advanced Prostate Carcinoma

The research base for Flutan in the context of advanced prostatic carcinoma is primarily founded upon large-scale Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving men, typically adult and older adult males, who were commencing therapy for metastatic or locally advanced disease. Researchers monitored outcomes over defined time intervals, with studies evaluating whether the addition of Flutan to medical or surgical castration was associated with measurements of major clinical endpoints.

Research examined outcomes such as Overall Survival and the Time to Disease Progression. Studies monitored readings in the Prostate-Specific Antigen (PSA) biomarker levels. Findings describe patterns observed in these large studies that were used in the initial regulatory review for the indication. Studies also explored short-term symptom activity, focusing on episodes where symptoms become more noticeable, examining symptom patterns during periods of heightened symptom activity, such as a tumor flare, which can occur when starting certain primary hormonal treatments.

Evidence for Addressing Hyperandrogenism Symptoms in Women

Research has also observed Flutan in contexts involving conditions characterized by fluctuating or episodic manifestations, specifically in populations presenting with symptoms associated with hyperandrogenism in women. The evidence base here is generally composed of smaller-scale Randomized Clinical Trials and various observational studies, particularly in populations presenting with manifestations such as excessive hair growth (hirsutism) and hormonal-driven acne.

Studies were designed to quantify objective measures related to symptomatic presentation. Research examined outcomes using objective tools that quantify symptomatic presentation, such as standardized Hirsutism Scores and assessments of Acne Severity. Findings indicate that studies observed symptom patterns related to readings of these measurements over defined time intervals, typically ranging from six months to one year. This research provides context but not individual predictions, and the evidence base for this application is considered less extensive than the oncology research.


Long-term Studies and Duration of Follow-up

For advanced prostate carcinoma, major RCTs often included long-term follow-up periods, with observation durations extending to two, five, or more years to adequately assess endpoints like overall survival. This research describes long-term group patterns related to disease progression. However, comparative evidence against other recently developed compounds is limited.

In contrast, evidence derived from settings with varying symptom burdens for hyperandrogenism in women typically relies on medium-term follow-up, generally lasting up to a year. There is limited information for long-term outcomes in this context. Consequently, the characteristics of reported patterns beyond this medium-term follow-up are not fully established, and data are still emerging.


Areas of Research Uncertainty and Study Gaps

One key area of discussion in scientific reviews is the variability of findings across the different authoritative meta-analyses related to overall survival in prostate cancer. Findings were mixed, with some analyses reporting patterns that suggested a small or inconsistent finding when Flutan was studied alongside castration. This illustrates that research highlights what is known, and what is still uncertain.

In the studies exploring hyperandrogenism symptoms, a primary limitation is that sample sizes were modest when compared to the oncology trials. Therefore, the results apply only to the populations studied under the specific conditions of the research. Comparative evidence is lacking against the full range of other agents currently used for these symptoms. Overall, certainty remains low regarding the long-term data available for this compound.

Key Studies & References Flutamide Tablets, 250 mg, oral Product Monograph (Health Canada regulatory document providing context for indication and studied populations)

Frequently Asked Questions (FAQ)

Common questions about Flutan (FAQ)


Q: Is Flutan a type of antibiotic, pain reliever, or something else?

A: Flutan (Flutamide) is classified in regulatory documents as a Nonsteroidal Antiandrogen (NSAA) and an Antineoplastic Agent. This means it belongs to a class of hormonal agents that primarily works to counteract the stimulating effects of male hormones on specific tissues. It is not classified as an antibiotic (used to fight bacterial infections) or a general pain reliever.


Q: Can Flutan be taken with multivitamins?

A: Official information advises caution regarding various medicinal products and supplements. Specific components found in some multivitamins, such as Vitamin D3 and Iron Sulfate, have been noted in research as having potential drug interaction profiles with Flutan. Official guidance suggests that all supplements and other products should be reviewed with a healthcare professional to determine potential interactions.


Q: What should I do if I experience a mild stomach upset while taking Flutan?

A: Gastrointestinal effects like diarrhea, nausea, and vomiting are documented as 'Very Common' adverse reactions in official labeling. Official guidance suggests that a healthcare professional be consulted regarding symptoms. To help alleviate discomfort, information suggests that nutritional adjustments, such as eating small, frequent meals, are sometimes recommended.


Q: Is Flutan affected by drinking alcohol?

A: Regulatory safety restrictions include a caution to avoid the 'excessive consumption of alcohol.' This caution is related to the documented risk of severe hepatic injury (liver damage) associated with Flutan.


Q: Is it possible to become resistant to Flutan over time?

A: The official research base discusses long-term patterns related to a condition called 'antiandrogen withdrawal syndrome.' This phenomenon involves a paradoxical response in some patients where stopping Flutan is associated with a temporary decrease in disease markers, which may suggest a complex pattern of action over time.


Q: What types of drug-to-drug interactions are considered most important for Flutan?

A: Regulatory documents establish important interactions involving certain Oral Anticoagulants (e.g., Warfarin) due to the risk of increased bleeding. Other critical interactions involve substances that affect specific liver enzymes (CYP1A2/CYP3A4), which may require dose adjustment or close monitoring by a professional.


Q: Can people with diabetes safely use Flutan?

A: Diabetes is not listed as a formal contraindication in the official prescribing information for Flutan. However, caution is noted for patients with certain underlying conditions. Research has examined Flutan in contexts involving insulin resistance and related metabolic disorders without classifying diabetes as a strict exclusion criterion.


Q: Can Flutan be stopped suddenly, or does it require a gradual reduction?

A: The official prescribing information mandates immediate discontinuation if laboratory evidence of severe liver injury is found. Otherwise, cessation of Flutan may be associated with the described 'antiandrogen withdrawal syndrome,' which means stopping the medication may result in temporary effects related to the condition being treated.


Q: How does Flutan differ from similar medications I've heard of?

A: Official classifications state that Flutan (Flutamide) was the first nonsteroidal antiandrogen (NSAA) to be made available. Official safety information notes its profile is associated with a common occurrence of gastrointestinal effects, such as diarrhea.


Q: Why do some people refer to Flutan as a 'new' drug?

A: Flutan's active ingredient, Flutamide, was first approved in the late 1980s. While not a recent discovery, its introduction marked a significant advancement, as it was the first nonsteroidal antiandrogen available. This historical context sometimes leads to its identification as a 'newer' type of hormonal therapy compared to older methods.


Q: How long does Flutan typically take to start having an effect?

A: Pharmacokinetic data shows that the active metabolite of Flutan is rapidly formed, reaching its maximum levels in the body approximately two hours after intake. However, in studies related to treating symptoms of hyperandrogenism, the observed peak benefit often occurs after a more extended period, ranging from six months to one year of consistent use.


Q: Is it normal to feel slightly dizzy when first starting Flutan?

A: Official regulatory information lists dizziness as a less common side effect associated with Flutan use. Other central nervous system effects, such as drowsiness, have also been documented. These types of effects usually appear during the initial phase of treatment.


Q: Does Flutan cause long-term side effects that I should be aware of?

A: Medical literature concerning long-term use of antiandrogen therapies, including Flutan, discusses potential associations with effects like bone thinning (osteoporosis) in specific patient populations. The official warnings mainly focus on the risk of severe liver injury, which requires mandated periodic monitoring, especially in the first four months of therapy.


Q: Are allergic reactions to Flutan common?

A: Allergic manifestations, which involve symptoms like itching, rash, or swelling, are described as rare in regulatory-supported medical literature. While any drug can potentially cause a reaction, severe allergic events are less common than other adverse events, such as gastrointestinal disturbances.


Q: Does Flutan require any specific tests before or during its use?

A: Yes, due to the documented risk of severe hepatic injury, official regulatory documents mandate that Liver Function Tests (serum transaminase levels) must be measured. These tests are required prior to starting treatment and periodically thereafter, typically on a monthly basis for the first four months.


Q: Are there different strengths or forms of Flutan available?

A: Flutan is officially supplied in an oral capsule dosage form. The medication is commonly available in a 125 mg or 250 mg strength for adult use, according to prescribing information.


Q: Can I crush or split Flutan tablets?

A: Official guidance for the capsule form of Flutan states that the contents of the capsules can be opened and mixed with soft foods if needed. However, regulatory guidance indicates that the tablet form is typically intended to be swallowed whole and not split or crushed.


Q: Does Flutan have any effects on mood or sleep?

A: Yes, official side effect profiles include effects on mental status and sleep, such as drowsiness, difficulty sleeping (insomnia), anxiety, and depression. These are typically categorized as less common or rare effects in the clinical documentation.


Q: Is there a risk of withdrawal symptoms if Flutan is stopped?

A: Regulatory-supported medical literature describes an 'antiandrogen withdrawal syndrome' that can occur after Flutan is stopped. This means that upon stopping the medication, a temporary biological change may be observed related to the condition being treated.


Q: Why does the official guidance say Flutan is not for certain groups of people?

A: Official guidance excludes populations due to specific, documented risks identified during regulatory review. For example, Flutan is contraindicated in pregnant women due to the risk of fetal harm or birth defects, and in patients with severe hepatic impairment due to the risk of fatal hepatic failure.


Q: Is Flutan available as a generic medication?

A: Yes, the active ingredient is Flutamide, which is the non-proprietary or generic name for the compound. It has been sold under various trade names like Flutan, Eulexin, Drogenil, and Niftolide, and is generally available in generic form.

How should Flutan be stored and disposed of?

How to Store and Dispose of Flutan

Flutan (Flutamide) capsules must be stored according to official regulatory specifications to maintain product integrity.

Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 to 25 C (68 to 77 F). Avoid excessive heat and freezing.
Protection Keep the medication in its original, closed container and protect it from moisture and direct light.
Safety The product must be stored out of the reach of children.

Disposal Instructions

Unused or expired Flutan should be taken to an official drug take-back program. If a take-back program is unavailable, the medicine must be prepared for household trash disposal by mixing it with an unappealing substance before sealing it in a bag. Flutan must not be flushed down the toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flutan found in:

A-Z Index: